United States · Bill · HR
H.R. 2139 (117th)
Medicare Drug Price Negotiation Act
Introduced
23 March 2021
Last action
24 March 2021 · Referred
Status
Referred to the Subcommittee on Health.
Sponsors
Rep. Doggett, Lloyd [D-TX-37], Sen. Welch, Peter [D-VT], Rep. Bush, Cori [D-MO-1], Rep. Khanna, Ro [D-CA-17], Rep. Pocan, Mark [D-WI-2], Rep. Jayapal, Pramila [D-WA-7], Rep. Cohen, Steve [D-TN-9], Rep. DeLauro, Rosa L. [D-CT-3], Rep. Tlaib, Rashida [D-MI-12], Rep. Wasserman Schultz, Debbie [D-FL-25], Rep. Neguse, Joe [D-CO-2], Rep. Omar, Ilhan [D-MN-5], Rep. Schakowsky, Janice D. [D-IL-9], Rep. DeFazio, Peter A. [D-OR-4], Rep. DeSaulnier, Mark [D-CA-10], Rep. Grijalva, Raúl M. [D-AZ-7], Sen. Kim, Andy [D-NJ], Rep. Waters, Maxine [D-CA-43], Rep. García, Jesús G. "Chuy" [D-IL-4], Rep. Bonamici, Suzanne [D-OR-1], Rep. Levin, Andy [D-MI-9], Rep. Jones, Mondaire [D-NY-17], Rep. Lawrence, Brenda L. [D-MI-14], Rep. Yarmuth, John A. [D-KY-3], Rep. Garcia, Sylvia R. [D-TX-29]
Subjects
Healthcare
Source updated
21 January 2026
Summary
Medicare Drug Price Negotiation Act This bill makes a series of changes relating to the prices of prescription drugs under the Medicare prescription drug benefit and Medicare Advantage (MA) prescription drug plans (PDPs). Under current law, the Centers for Medicare & Medicaid Services (CMS) may neither negotiate the prices of covered drugs nor establish a formulary. The bill repeals these restrictions and instead specifically requires the CMS to (1) negotiate the prices of covered drugs; and (2) either establish a formulary for covered drugs, or require changes to PDP formularies that take into account CMS negotiations. If the CMS is unable to negotiate an appropriate price for a drug in accordance with certain criteria, the price must be the lowest of three specified options (e.g., the median price in other countries). The CMS must identify drugs that are subject to negotiation, with priority given to certain categories of drugs based on usage and cost. Additionally, drug manufacturers must issue rebates to the CMS for drugs dispensed to eligible low-income individuals. Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
23 March 2021
Referred
Referred to the Subcommittee on Health.
Source: Committee
23 March 2021
Introduced
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
23 March 2021
Introduced
Introduced in House
Source: IntroReferral
23 March 2021
Introduced
Introduced in House
Source: IntroReferral
24 March 2021
Referred
Referred to the Subcommittee on Health.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 23 March 2021 · Download file
Documents
3 official files
Introduced in House (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House (text)
Introduced in House · EN · 23 March 2021
Introduced in House (PDF)
Introduced in House · EN · 23 March 2021
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 23 March 2021
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. Doggett, Lloyd [D-TX-37] · D · Sponsor
- Sen. Welch, Peter [D-VT] · D · Sponsor
- Rep. Bush, Cori [D-MO-1] · D · Sponsor
- Rep. Khanna, Ro [D-CA-17] · D · Sponsor
- Rep. Pocan, Mark [D-WI-2] · D · Sponsor
- Rep. Jayapal, Pramila [D-WA-7] · D · Sponsor
- Rep. Cohen, Steve [D-TN-9] · D · Sponsor
- Rep. DeLauro, Rosa L. [D-CT-3] · D · Sponsor
- Rep. Tlaib, Rashida [D-MI-12] · D · Sponsor
- Rep. Wasserman Schultz, Debbie [D-FL-25] · D · Sponsor
- Rep. Neguse, Joe [D-CO-2] · D · Sponsor
- Rep. Omar, Ilhan [D-MN-5] · D · Sponsor
- Rep. Schakowsky, Janice D. [D-IL-9] · D · Sponsor
- Rep. DeFazio, Peter A. [D-OR-4] · D · Sponsor
- Rep. DeSaulnier, Mark [D-CA-10] · D · Cosponsor
- Rep. Grijalva, Raúl M. [D-AZ-7] · D · Cosponsor
- Sen. Kim, Andy [D-NJ] · D · Cosponsor
- Rep. Waters, Maxine [D-CA-43] · D · Cosponsor
- Rep. García, Jesús G. "Chuy" [D-IL-4] · D · Cosponsor
- Rep. Bonamici, Suzanne [D-OR-1] · D · Cosponsor
- Rep. Levin, Andy [D-MI-9] · D · Cosponsor
- Rep. Jones, Mondaire [D-NY-17] · D · Cosponsor
- Rep. Lawrence, Brenda L. [D-MI-14] · D · Cosponsor
- Rep. Yarmuth, John A. [D-KY-3] · D · Cosponsor
- Rep. Garcia, Sylvia R. [D-TX-29] · D · Cosponsor
- · hsif00 · Standing
- · hswm00 · Standing
Related records
- related to → Medicare Drug Price Negotiation Act
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/2139
- Open data entity: https://api.congress.gov/v3/bill/117/hr/2139
- us · 117-hr-2139 · source updated 21 January 2026